Sequana Medical

75 articles with Sequana Medical

• Sequana Medical announces additional patents for DSR® in China and the United States

  3/22/2023

  Sequana Medical NV announces further strengthening of the intellectual property portfolio for its DSR program.

• Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure

  3/1/2023

  Sequana Medical NV announces positive results from its Phase 1 single-center, single-arm, single-dose trial with its second-generation DSR product.

• Sequana Medical announces results of Extraordinary General Meeting of Shareholders

  2/10/2023

  Sequana Medical NV announces that all proposed resolutions submitted to the extraordinary general meeting of shareholders were approved at the meeting held February 10, 2023 at 09:00 am CET.

• Sequana Medical announces 2022 Full Year Results and 2023 Outlook

  2/9/2023

  Sequana Medical NV announces its financial results for the year ended 31 December 2022, and provides a business update and outlook for 2023.

• Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure

  2/8/2023

  Sequana Medical NV announces the successful completion of its GLP animal studies, demonstrating the safety of its second-generation DSR product, following chronic exposure.

• Sequana Medical Notice of 2022 Full Year Results and Business Update

  2/2/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its full year results ended 31 December 2022 on Thursday, 9 February 2023.

• Sequana Medical announces grant of additional DSR® patent in United States

  2/1/2023

  Ghent, Belgium – 1 February 2023– Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces the grant of an additional US patent for its DSR program.

• Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023

  1/11/2023

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, invites the holders of securities issued by the Company to attend the Extraordinary General Meeting of Shareholders on Friday, 10 February 2023.

• Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON

  11/15/2022

  Sequana Medical NV announces positive top-line results from SAHARA, the Phase 2a study using its first-generation DSR product.

• Sequana Medical to present at Jefferies 2022 London Healthcare Conference

  11/8/2022

  Sequana Medical NV announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to 17 November 2022.

• Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)

  10/25/2022

  Sequana Medical NV announces positive top-line results from the North American pivotal POSEIDON study of the alfapump, a fully implantable, wirelessly charged, breakthrough device for the treatment of recurrent or refractory ascites due to liver cirrhosis.

• Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®

  10/21/2022

  Sequana Medical NV announces that data from the Roll-In Cohort of POSEIDON1, its North American pivotal alfapump study, have been selected for a poster presentation at the American Association for the Study of Liver Diseases The Liver Meeting, taking place in Washington, DC from 4 to 8 November 2022.

• Sequana Medical announces H1 2022 results and provides business update

  9/8/2022

  Sequana Medical NV announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.

• Sequana Medical Notice of 2022 Half Year Results and Business Update

  9/1/2022

  Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022.

• Alexandra Clyde appointed to Sequana Medical Board of Directors

  8/25/2022

  Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company.

• Sequana Medical secures EUR 10 million loan facility with Kreos Capital

  7/20/2022

  Ghent, Belgium – 20 July 2022– Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, announces it has entered into a secured loan facility agreement of EUR 10 million with Kreos Capital VI Limited.

• Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

  7/19/2022

  Sequana Medical NV announces the completion of enrollment in its Phase 2a SAHARA proof-of-concept study using its first-generation DSR product as treatment for congestive heart failure.

• Doug Kohrs appointed to Sequana Medical Board of Directors

  7/19/2022

  Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company.

• Sequana Medical announces 2021 Full Year Results and 2022 Outlook

  4/12/2022

  Sequana Medical NV announces its financial results for the year ended 31 December 2021, and provides a business update and an outlook for the remainder of 2022.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.